BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

434 related articles for article (PubMed ID: 25408144)

  • 21. Comparison of arsenic methylation capacity and polymorphisms of arsenic methylation genes between bladder cancer and upper tract urothelial carcinoma.
    Huang CY; Lin YC; Shiue HS; Chen WJ; Su CT; Pu YS; Ao PL; Hsueh YM
    Toxicol Lett; 2018 Oct; 295():64-73. PubMed ID: 29859237
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prognostic and predictive value of epigenetic biomarkers and clinical factors in upper tract urothelial carcinoma.
    Xiong G; Liu J; Tang Q; Fan Y; Fang D; Yang K; Xie F; Zhang M; Zhang L; Liu L; Zhang C; Yao L; Yang L; Ci W; Zhao W; Gong Y; He Q; Gong K; He Z; Wang G; Li X; Guo Y; Zhou L
    Epigenomics; 2015 Aug; 7(5):733-44. PubMed ID: 25912368
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The prognostic significance of vasohibin-1 expression in patients with upper urinary tract urothelial carcinoma.
    Miyazaki Y; Kosaka T; Mikami S; Kikuchi E; Tanaka N; Maeda T; Ishida M; Miyajima A; Nakagawa K; Okada Y; Sato Y; Oya M
    Clin Cancer Res; 2012 Aug; 18(15):4145-53. PubMed ID: 22675166
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prognostic value of microRNA expression pattern in upper tract urothelial carcinoma.
    Izquierdo L; Ingelmo-Torres M; Mallofré C; Lozano JJ; Verhasselt-Crinquette M; Leroy X; Colin P; Comperat E; Roupret M; Alcaraz A; Mengual L
    BJU Int; 2014 May; 113(5):813-21. PubMed ID: 24180461
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comprehensive Genomic Characterization of Upper Tract Urothelial Carcinoma.
    Moss TJ; Qi Y; Xi L; Peng B; Kim TB; Ezzedine NE; Mosqueda ME; Guo CC; Czerniak BA; Ittmann M; Wheeler DA; Lerner SP; Matin SF
    Eur Urol; 2017 Oct; 72(4):641-649. PubMed ID: 28601352
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Upper urinary tract urothelial carcinoma in eastern Taiwan: high proportion among all urothelial carcinomas and correlation with chronic kidney disease.
    Chen CY; Liao YM; Tsai WM; Kuo HC
    J Formos Med Assoc; 2007 Dec; 106(12):992-8. PubMed ID: 18194904
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Evaluation of the prognostic significance of altered mammalian target of rapamycin pathway biomarkers in upper tract urothelial carcinoma.
    Bagrodia A; Krabbe LM; Gayed BA; Kapur P; Bernstein I; Xie XJ; Wood CG; Karam JA; Weizer AZ; Raman JD; Remzi M; Rioux-Leclerq N; Haitel A; Roscigno M; Bolenz C; Bensalah K; Sagalowsky AI; Shariat SF; Lotan Y; Margulis V
    Urology; 2014 Nov; 84(5):1134-40. PubMed ID: 25443916
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Distinct patterns and behaviour of urothelial carcinoma with respect to anatomical location: how molecular biomarkers can augment clinico-pathological predictors in upper urinary tract tumours.
    Yates DR; Catto JW
    World J Urol; 2013 Feb; 31(1):21-9. PubMed ID: 22986906
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Mutational Analysis of 472 Urothelial Carcinoma Across Grades and Anatomic Sites.
    Nassar AH; Umeton R; Kim J; Lundgren K; Harshman L; Van Allen EM; Preston M; Dong F; Bellmunt J; Mouw KW; Choueiri TK; Sonpavde G; Kwiatkowski DJ
    Clin Cancer Res; 2019 Apr; 25(8):2458-2470. PubMed ID: 30593515
    [TBL] [Abstract][Full Text] [Related]  

  • 30. C-reactive protein: a biomarker of survival in patients with localized upper tract urothelial carcinoma treated with radical nephroureterectomy.
    Obata J; Kikuchi E; Tanaka N; Matsumoto K; Hayakawa N; Ide H; Miyajima A; Nakagawa K; Oya M
    Urol Oncol; 2013 Nov; 31(8):1725-30. PubMed ID: 23141922
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of concomitant variant histology on the prognosis of patients with upper urinary tract urothelial carcinoma after radical nephroureterectomy.
    Shibing Y; Turun S; Qiang W; Junhao L; Haichao Y; Shengqiang Q; Ping H; Dehong C
    Urol Oncol; 2015 May; 33(5):204.e9-16. PubMed ID: 25800374
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Dysregulation of mammalian target of rapamycin pathway in upper tract urothelial carcinoma.
    Munari E; Fujita K; Faraj S; Chaux A; Gonzalez-Roibon N; Hicks J; Meeker A; Nonomura N; Netto GJ
    Hum Pathol; 2013 Dec; 44(12):2668-76. PubMed ID: 24074531
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Accurate detection of upper tract urothelial carcinoma in tissue and urine by means of quantitative GDF15, TMEFF2 and VIM promoter methylation.
    Monteiro-Reis S; Leça L; Almeida M; Antunes L; Monteiro P; Dias PC; Morais A; Oliveira J; Henrique R; Jerónimo C
    Eur J Cancer; 2014 Jan; 50(1):226-33. PubMed ID: 24100025
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Loss of DAB2IP expression in human urothelial carcinoma is associated with poorer recurrence-free survival.
    Jou YC; Tsai YS; Chen SY; Hsieh HY; Tsai HT; Tzai TS
    Virchows Arch; 2016 Jun; 468(6):733-40. PubMed ID: 27003158
    [TBL] [Abstract][Full Text] [Related]  

  • 35. European Association of Urology Guidelines on Upper Urinary Tract Urothelial Cell Carcinoma: 2015 Update.
    Rouprêt M; Babjuk M; Compérat E; Zigeuner R; Sylvester RJ; Burger M; Cowan NC; Böhle A; Van Rhijn BW; Kaasinen E; Palou J; Shariat SF
    Eur Urol; 2015 Nov; 68(5):868-79. PubMed ID: 26188393
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prospective analysis of Ki-67 as an independent predictor of oncologic outcomes in patients with high grade upper tract urothelial carcinoma.
    Krabbe LM; Bagrodia A; Lotan Y; Gayed BA; Darwish OM; Youssef RF; John G; Harrow B; Jacobs C; Gaitonde M; Sagalowsky AI; Shariat SF; Kapur P; Margulis V
    J Urol; 2014 Jan; 191(1):28-34. PubMed ID: 23871758
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pretreatment lymphocyte-monocyte ratio as a potential prognostic factor in a cohort of patients with upper tract urothelial carcinoma.
    Hutterer GC; Sobolev N; Ehrlich GC; Gutschi T; Stojakovic T; Mannweiler S; Pummer K; Zigeuner R; Pichler M; Dalpiaz O
    J Clin Pathol; 2015 May; 68(5):351-5. PubMed ID: 25661796
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The role of GATA binding protein 3 in the differential diagnosis of collecting duct and upper tract urothelial carcinomas.
    Gonzalez-Roibon N; Albadine R; Sharma R; Faraj SF; Illei PB; Argani P; Ertoy D; Allaf ME; Netto GJ
    Hum Pathol; 2013 Dec; 44(12):2651-7. PubMed ID: 24071011
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Genomic Characterization of Upper Tract Urothelial Carcinoma.
    Sfakianos JP; Cha EK; Iyer G; Scott SN; Zabor EC; Shah RH; Ren Q; Bagrodia A; Kim PH; Hakimi AA; Ostrovnaya I; Ramirez R; Hanrahan AJ; Desai NB; Sun A; Pinciroli P; Rosenberg JE; Dalbagni G; Schultz N; Bajorin DF; Reuter VE; Berger MF; Bochner BH; Al-Ahmadie HA; Solit DB; Coleman JA
    Eur Urol; 2015 Dec; 68(6):970-7. PubMed ID: 26278805
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prognostic value of plasma fibrinogen levels in patients with localized upper tract urothelial carcinoma.
    Tanaka N; Kikuchi E; Matsumoto K; Hayakawa N; Ide H; Miyajima A; Nakamura S; Oya M
    BJU Int; 2013 May; 111(6):857-64. PubMed ID: 22757942
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.